



(51) International Patent Classification:

C07D 471/04 (2006.01) **A61K 31/4188** (2006.01)
C07D 401/06 (2006.01) **A61K 31/4192** (2006.01)
C07D 401/10 (2006.01) **A61K 31/4196** (2006.01)
C07D 401/14 (2006.01) **A61K 31/423** (2006.01)
C07D 403/02 (2006.01) **A61K 31/5025** (2006.01)
C07D 403/06 (2006.01) **A61K 31/517** (2006.01)
C07D 403/14 (2006.01) **A61K 31/519** (2006.01)
A61K 31/437 (2006.01) **A61P 3/10** (2006.01)
A61K 31/407 (2006.01) **A61P 13/12** (2006.01)
A61K 31/416 (2006.01) **A61P 17/06** (2006.01)
A61K 31/4162 (2006.01) **A61P 17/00** (2006.01)
A61K 31/4184 (2006.01) **A61P 37/00** (2006.01)

(21) International Application Number:

PCT/CN2010/076199

(22) International Filing Date:

20 August 2010 (20.08.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/236,274 24 August 2009 (24.08.2009) US

(71) **Applicant** (for all designated States except US): **ASCEPION PHARMACEUTICALS, INC.** [CN/CN]; BioBay Building A3, Suite 102, 218 Xinghu St., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **JIANG, Shan** [US/US]; 44 Hills Point Road, Trumbull, Connecticut 06611 (US). **XING, Xinglong** [CN/CN]; Fuhuayuan Community, Building 23, Unit 302, 1 Jinji Lake Road, Suzhou,

Jiangsu 215006 (CN). **WANG, Qishan** [CA/US]; 7451 Ironwood Ct., Pleasanton, California 94566 (US). **KONG, Ren** [CN/CN]; Jincheng Apartment, Building 5, Unit 803, 58 Qihong Road, Suzhou, Jiangsu 215000 (CN).

(74) **Agent:** **SUNRAY INTELLECTUAL PROPERTY ATTORNEYS**; Suite 1212, Tomson Commercial Building, 710 Dong Fang Road, Pudong, Shanghai 200122 (CN).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) **Title:** 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS



(I)



(II)

(57) **Abstract:** The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFR β c-Kit, CSFIR, or EphA2.